SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
SEC Accession No. 0001213900-22-079815
Filing Date
2022-12-14
Accepted
2022-12-14 16:45:52
Documents
9

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO FORM F-1 ea170090-f1a2_biondvax.htm F-1/A 119151
2 FORM OF UNDERWRITING AGREEMENT ea170090ex1-1_biondvax.htm EX-1.1 233687
3 ARTICLES OF ASSOCIATION OF BIONDVAX PHARMACEUTICALS LTD ea170090ex3-1_biondvax.htm EX-3.1 296004
4 FORM OF PRE-FUNDED WARRANT ea170090ex4-4_biondvax.htm EX-4.4 119237
5 FORM OF EXCHANGEABLE WARRANT ea170090ex4-5_biondvax.htm EX-4.5 99669
6 FORM OF NON-EXCHANGEABLE WARRANT ea170090ex4-6_biondvax.htm EX-4.6 104706
7 OPINION OF GROSS & CO ea170090ex5-1_biondvax.htm EX-5.1 7973
8 AMENDMENT AGREEMENT, DATED AUGUST 9, 2022, BETWEEN BIONDVAX PHARMACEUTICALS LTD. ea170090ex10-14_biondvax.htm EX-10.14 146356
9 GRAPHIC ex5-1_001.jpg GRAPHIC 10486
  Complete submission text file 0001213900-22-079815.txt   1142430
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-1/A | Act: 33 | File No.: 333-267648 | Film No.: 221462719
SIC: 2836 Biological Products, (No Diagnostic Substances)